Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A double-blind crossover trial was completed in 15 patients with moderate hypertension and the effects of propranolol (Inderal) 80 mg twice a day and atenolol (Tenormin) 100 mg twice a day were assessed on blood pressure, pulse rate and plasma renin activity (PRA), while patients were maintained on 1 cyclopenthiazide tablet (Navidrex K) per day. Both agents caused a significant reduction in blood pressure and pulse rate with patients at rest and during exercise. Plasma renin activity was significantly reduced by both agents in subjects with normal and high renin levels (with PRA 2-8 ng/ml/h and greater than 8 ng/ml/h respectively). Blood pressure responses could not be correlated with renin status or reduction in pulse rate. No adverse effects were attributable to either of the two beta-adrenergic blocking agents and we concluded that a beta1-selective agent, which has the advantage of not aggravating bronchospasm, can replace the non-selective propranolol.
 ...
PMID:Effects of propranolol and atenolol on blood pressure and plasma renin activity in patients with moderate hypertension. 34 73

Sixty-two patients with hypertension who were treated with a free combination of Slow Trasicor or Trasicor and Navidrex K were transferred to a fixed combination tablet, Trasidrex (slow oxprenolol 160 mg + cyclopenthiazide 0.25 mg). Blood pressure control was marginally improved and there was no increase in side-effects.
 ...
PMID:Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice. 72 Jul 40

The antihypertensive efficacy and metabolic effects of cyclopenthiazide 125 micrograms were compared with cyclopenthiazide 500 micrograms in patients with non-insulin dependent diabetes and hypertension in a double blind, randomized crossover study. After a 6-week placebo period 24 patients with non-insulin dependent diabetes mellitus, stabilized on diet or oral hypoglycaemic agents, who had a mean diastolic blood pressure between 90 and 120 mmHg after receiving placebo for 6 weeks were given 125 micrograms or 500 micrograms cyclopenthiazide for 12 weeks. Patients then received placebo for a further 6-week period, following which they received the alternate treatment dosage for 12 weeks. There were no differences between doses in their antihypertensive effects. While 500 micrograms significantly reduced systolic and diastolic blood pressures, only diastolic pressure was significantly reduced by 125 micrograms from pre-treatment values. The higher dose of cyclopenthiazide had greater effects on measures of diabetic control than did the 125 micrograms dose and the rise in blood glucose after 12 weeks' treatment with 500 micrograms was significantly different from pre-treatment values. Cyclopenthiazide 125 micrograms had significantly less effect on triglycerides, potassium and urate, than did 500 micrograms. Cyclopenthiazide 500 micrograms resulted in a significant fall in serum potassium from pre-treatment values. There were no intertreatment differences in the other variables measured. Cyclopenthiazide 125 micrograms is as effective as 500 micrograms in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients. The higher dose had more pronounced adverse effects on glucose control and serum concentrations of triglycerides, potassium and urate.
 ...
PMID:The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. 180 32